Endothelium-derived relaxing factor is an endogenous vasodilator in man
Open Access
- 19 July 1989
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 97 (3) , 639-641
- https://doi.org/10.1111/j.1476-5381.1989.tb11998.x
Abstract
Removal of venous endothelium in man leads to vasoconstriction and loss of dilator response to acetylcholine but not to glyceryl trinitrate. This pattern of responses can be accounted for by loss of endotheliumderived relaxing factor (EDRF), but not by loss of prostacyclin. This provides the first direct evidence for endothelium-dependent dilatation in man in vivo, and suggests that basal release of EDRF is a determinant of resting venous tone.This publication has 10 references indexed in Scilit:
- Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug.Circulation, 1988
- Functional and anatomical recovery of endothelium after denudation of coronary arteryAmerican Journal of Physiology-Heart and Circulatory Physiology, 1988
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988
- Mechanisms of action of noradrenaline and carbachol on smooth muscle of guinea‐pig anterior mesenteric artery.The Journal of Physiology, 1984
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980
- Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endotheliumThrombosis Research, 1977
- Simplified method for measuring compliance of superficial veinsCardiovascular Research, 1971
- THE EFFECTS ON VENOUS ENDOTHELIUM OF ALTERATIONS IN BLOOD FLOW THROUGH THE VESSELS IN VEIN WALLS, AND THE POSSIBLE RELATION TO THROMBOSISAnnals of Surgery, 1947